PDCD1 and metastatic melanoma: In their phase 1 clinical trial, they investigated the safety and feasibility of FMT and the combination of FMT and reinduction of anti–PD-1 immunotherapy in 10 patients with anti–PD-1–refractory metastatic melanoma.